2005/07/24 by Brendan Delaney, Kenneth E.L. McColl · 1 citation
Medicine · #Helicobacter pylori-related gastroenterology studies #Gastroesophageal reflux and treatments #Eosinophilic Esophagitis #Helicobacter pylori #Medicine #Gastroenterology #Gastro- #Reflux #Proton-pump inhibitor #Internal medicine #Disease #Gastric acid #Gastritis #Spirillaceae #Stomach
paper · doi:10.1111/j.1365-2036.2005.02607.x
openalex publication_date 2005/07/24 · openalex created_date 2016/06/24 · openalex updated_date 2026/07/29
Epidemiological studies demonstrate a negative association between Helicobacter pylori infection and gastro-oesophageal reflux disease and its complications. This might represent a protective effect because of the tendency for H. pylori infection to lower gastric acid secretion with advancing age. However, studies of the effect of H. pylori eradication on gastro-oesophageal reflux disease have failed to show any worsening of gastro-oesophageal reflux disease symptoms. Several interactions between H. pylori and proton-pump inhibitor therapy used to treat gastro-oesophageal reflux disease need to be considered. Helicobacter pylori infection improves the control of gastric acidity by proton-pump inhibitors and this produces a small advantage in clinical control of reflux disease. The infection prevents rebound acid hypersecretion occurring when proton-pump inhibitor therapy is discontinued. However, concerns have been expressed that the body gastritis induced by proton-pump inhibitor therapy in H. pylori-infected subjects might increase the risk of gastric cancer. At present, it is unclear whether H. pylori should be eradicated in gastro-oesophageal reflux disease patients.